the transglutaminase coagulation factor XIIIA (FXIIIA) was one of the most abundant proteins contained in the BMCMC releasates. Mast cell-deficient mice exhibited increased FXIIIA plasma and activity levels as well as reduced bleeding times, indicating that mast cells are more efficient in their ability to downregulate FXIIIA than in contributing to its amounts and functions in homeostatic conditions. We found that human chymase and mouse mast cell protease-4 (the mouse homologue of human chymase) had the ability to reduce FXIIIA levels and function via proteolytic degradation. Moreover, we found that chymase deficiency led to increased FXIIIA amounts and activity, as well as reduced bleeding times in homeostatic conditions and during sepsis. Conclusions: Our study indicates that the mast cell protease content can shape its releasate proteome. Moreover, we found that chymase plays an important role in the regulation of Mast cells are hematopoietic progenitor-derived, granulecontaining immune cells that are widely distributed in tissues that interact with the external environment, such as the skin and mucosal tissues. Although it is well known that mast cells are significantly involved in IgE-mediated allergic reactions, recent studies have shown that mast cells and their granule proteases have pleiotropic regulatory roles in other immunological responses and diseases, such as in bacterial and parasite infections, sepsis, autoimmune disease, and cancer. 1 Many of these studies, however, were biased to investigate mouse models in which mast cells were hypothesized to play key roles on the basis of in vitro studies or conditions in which mast cell numbers or their mediators were increased, suggesting that our understanding of the contribution of mast cells to health and disease is limited. In this study, we adopted an unbiased approach with the potential to provide a more comprehensive assessment of how mast cells may influence biological processes by characterizing mast cell releasate proteomes via mass spectrometry analysis.
Mast cells express protease profiles that vary among species and different mast cell subsets. In humans, mast cells either express tryptase (a and b) only (known as the MC T subclass) or tryptase, chymase, and mast cell carboxypeptidase A (CPA) (known as the MC TC subclass). In mice, mast cells are divided into connective tissue (connective tissue mast cells [CTMCs] ) and mucosal mast cell (MMC) subtypes. CTMCs predominantly express the b-chymase, mouse mast cell protease 4 (mMCP-4), and the a-chymase mMCP-5, whereas MMCs predominantly express 2 different b-chymases, mMCP-1 and mMCP-2. In addition, in the C57BL/6 mouse background, CTMCs express a tetrameric tryptase (mMCP-6) as well as CPA. 2 We and others have shown that mast cell proteases can cleave certain mediators released by mast cells into inactive or active fragments. For example, we reported that mMCP-4, the mouse homologue of human chymase in substrate specificity, 3 prevents hyperinflammation in severe sepsis via proteolytic degradation of TNF. 4 Consequently, it is important to understand how mast cell phenotypes and their protease content may shape their mediator release profile on activation. Herein, we characterized the releasates generated by bone marrow derived-cultured mast cells (BMCMCs) and peritoneal cell-derived mast cells (PCMCs) following IgE-mediated activation as ''surrogates'' for MMCs and CTMCs, respectively. 5, 6 Our proteomics studies indicate that BMCMCs and PCMCs produced substantially different releasates. As a specific example, we observed that the transglutaminase coagulation factor XIIIA (FXIIIA) was one of the most abundant proteins in the IgEmediated BMCMC releasate. In contrast, the PCMC releasate did not contain FXIIIA. Therefore, we investigated the involvement of CTMC-specific proteases in the downregulation of FXIIIA, and we observed that mast cell chymase could proteolytically degrade FXIIIA and diminish its function during homeostatic and septic states.
METHODS
For detailed methods, including the mice used, experimental protocols and procedures, and statistical analysis, please see the Methods section in this article's Online Repository at www.jacionline.org.
RESULTS

Proteome profiling of mast cell releasates
To define the BMCMC and PCMC releasates following IgE-mediated activation, we used a mass spectrometry shotgun proteomics approach. Specifically, IgE-2, 4-dinitrophenylsensitized BMCMCs and PCMCs were stimulated with 2, 4-dinitrophenyl-human serum albumin antigen for 6 hours. Then, the supernatants were collected, concentrated, and subjected to LC-MS/MS to identify the IgE-mediated differentially produced proteins from these mast cells (Fig 1, A) . We identified 91 proteins that were unique to PCMCs (Table I; see Table E1 in this article's Online Repository at www.jacionline.org), 390 proteins that were unique to BMCMCs (Table II; see Table E2 in this article's Online Repository at www.jacionline.org), and 674 proteins that were extracellularly produced by both BMCMCs and PCMCs (Table III; see Table E3 in this article's Online Repository at www.jacionline.org) (Fig 1, B) . We associated the proteins identified in the releasates with functional annotations. By gene ontology analysis, the commonly enriched biological process categories in the BMCMC and PCMC releasates were linked to metabolic processes (eg, carbohydrate/ protein metabolism and glycolysis) as well as intracellular protein trafficking, protein folding, cell structure and motility, and endocytosis (Table III; see Table E4 on activation that may require the metabolic and actin cytoskeleton remodeling processes observed in our gene ontology analysis. Processes associated with protein alteration, such as amino acid, protein metabolism, and proteolysis, were the main processes found among the unique proteins contained in the PCMC releasates (see Table E5 in this article's Online Repository at www.jacionline.org). The enriched categories from the unique BMCMC releasates (not found in the PCMC releasates)
were associated with blood clotting, immune response regulation (eg, cytokine and chemokine-mediated signaling pathways), and immunity and defense (see Table E6 in this article's Online Repository at www.jacionline.org). These data suggest not only that BMCMCs produce factors related to immune response regulation but also that PCMCs either do not produce these factors or they are more efficient in their downregulation via proteolysis. Boldface indicates coagulation factor XIII A chain abundance in PCMC and BMCMC releasates.
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Mast cells produce and release FXIIIA on activation
Our proteomics study revealed that the transglutaminase FXIIIA was one of the most abundant proteins released by BMCMCs on activation. Transglutaminases are multifunctional proteins (eg, enzymatic and scaffolding functions) that are known to regulate cellular processes in homeostatic and disease states. 7 FXIIIA is 1 of 9 transglutaminases in humans, all of which (with the exception of band 4.2, which is catalytically inactive) share the same catalytic site sequence. FXIIIA becomes catalytically active once it dissociates from FXIIIB and a 37 AA peptide is cleaved from its N-terminus (the active form of FXIIIA is called FXIIIa). FXIIIA is best known for its involvement in fibrin cross-linking for clot stabilization, and it is the only transglutaminase known to be involved in the coagulation cascade. 8 FXIIIA deficiency can result in moderate to severe hemorrhagic diathesis. 9 Furthermore, FXIIIA can contribute to processes in which mast cells play a key role, such as wound healing, cell migration, and innate immunity. 10 FXIIIA is present in the cytoplasm of platelets and monocytes/ macrophages 11 ; however, FXIIIA expression has never been reported in mast cells.
By using western blot analysis, we estimated that BMCMCs contained 800 fg FXIIIA per cell (see Fig E1 in this article's Online Repository at www.jacionline.org), which is around 10-fold greater than what is reported for platelets. 12 There is evidence for FXIIIA entering the alternative secretory pathway; however, its secretion by an immune cell has not been demonstrated. 13 Our mass spectrometry data (Table II) and western blot analysis (Fig 2, A) indicate that IgE/antigenactivated BMCMCs secrete FXIIIA on activation.
In contrast to monocytes, 14 BMCMCs did not display increased FXIIIA mRNA expression after activation (Fig 2, B) , suggesting that FXIIIA protein is preformed in mast cells. Indeed, we observed that intracellular FXIIIA exhibited a typical granular pattern in BMCMCs (Fig 2, C) , confirming that FXIIIA is stored in mast cell granules.
Mast cell deficiency leads to increased FXIIIA levels and reduced bleeding time
To investigate the relative contribution of mast cells to FXIIIA plasma levels in homeostatic conditions, we examined the Cpa3-Cre; ROSA DTA/DTA mast cell-and basophil-deficient mice (a c-kit-independent mast cell-and basophil-deficient strain). 15 We found that Cpa3-Cre; ROSA DTA/DTA mice exhibited increased FXIIIA plasma (Fig 3, A and B) and FXIIIa activity levels (Fig 3,  C) , indicating that mast cells and/or basophils significantly contribute to downregulation of FXIIIA levels rather than contribute to the production of FXIIIA circulating pool in naive mice. To determine whether basophils contribute to FXIIIA downregulation, we used Mcpt8 DTR mice, which express human diphtheria toxin receptor only in basophils and in which basophils can be selectively depleted after a single intraperitonial injection of diphtheria toxin. 16 Plasma from basophil-depleted mice (Mcpt8 DTR/1 ) exhibited similar plasma FXIIIA amounts as did plasma from basophil-competent mice (Mcpt8 To determine the physiological impact of the increased FXIIIA and FXIIIa activity levels due to mast cell deficiency, we assessed bleeding times in Cpa3-Cre; ROSA DTA/DTA mice because bleeding time is a measurement that is directly linked to active FXIIIa levels. 17 We observed that Cpa3-Cre; ROSA DTA/DTA mice exhibited reduced bleeding times compared with their Boldface indicates abundance of mast cell specific proteases in PCMC and BMCMC releasates.
littermate controls (Fig 3, D) , suggesting that mast cell-mediated downregulation of FXIIIA amounts can influence clotting. Overall, our findings indicate that despite the ability of mast cells to produce FXIIIA, mast cells mainly contribute to the downregulation of FXIIIA levels and consequently reduce clotting during homeostatic conditions.
Mouse chymase downregulates FXIIIA levels and function via proteolysis PCMC lysates contain lower FXIIIA amounts compared with BMCMC lysates (240 fg FXIIIA per cell). Moreover, our mass spectrometry data revealed that PCMCs do not generate detectable amounts of FXIIIA in their supernatants on activation in contrast to BMCMCs (Table I; Fig 4) . This observation led us to hypothesize that PCMCs are more efficient in FXIIIA downregulation than in its production. Therefore, we decided to investigate mechanisms by which PCMCs downregulate FXIIIA levels. Previous studies using mouse recombinant mast cell proteases and nonspecific protease inhibitors suggested that mast cell proteases are able to downregulate certain cytokines and chemokines via proteolytic degradation. [18] [19] [20] [21] Our proteomics data showed that IgE/antigen-activated PCMCs generate releasates that are richer in their protease content compared with releasates generated by BMCMCs. In fact, mMCP-4, the mouse homologue of human chymase, 22 was one of the most abundant proteins found in the PCMC releasate and one of the least abundant among the BMCMC releasate proteins (Tables I  and II; Tables E1 and E2; see Fig E3 in this article's Online Repository at www.jacionline.org). This finding is in agreement with previous reports by us and other groups that BMCMCs generated from mice in the C57BL/6 background express low mMCP-4 levels. 4, 23, 24 As the FXIIIA amino acid sequence contains potential cleavage sites for chymase, 3 we investigated whether mMCP-4 can downregulate FXIIIA via proteolysis. To test this hypothesis, we used mMCP-4-deficient mice (Mcpt4 2/2 mice) that do not exhibit any marked defects in the concentrations of other mast cell proteases, including mMCP-5, mMCP-6, or CPA, in their peritoneal mast cells. 22 Our mass spectrometry data indicated that Mcpt4 1/1 PCMC releasates contained lower FXIIIA spectral count levels than did the releasates generated by Mcpt4 2/2 PCMCs (Fig 4, A) . Moreover, we found that the Mcpt4 1/1 PCMC lysates caused more extensive FXIIIA degradation than did the Mcpt4 2/2 PCMC lysates (Fig 4, B) , indicating that chymase contributes to FXIIIA fragmentation. Analysis of IgE/2, 4-dinitrophenyl-human serum albumin-activated PCMCs that were obtained from Similarly to the mast cell-and basophil-deficient mouse, Mcpt4 2/2 mice exhibited increased FXIIIA plasma (Fig 4, C  and D) and FXIIIa activity levels (Fig 4, E) , indicating that chymase significantly contributes to downregulate FXIIIA levels and function. Moreover, Mcpt4 2/2 mice exhibited reduced bleeding times compared with Mcpt4 1/1 mice (Fig 4, F) , suggesting that chymase-mediated downregulation of FXIIIA amounts also influences clotting.
Therefore, our data suggest that FXIIIA may be a potential target for mMCP-4 proteolytic activity, and hence mast cells contribute to FXIIIA downregulation.
Human chymase degrades FXIIIA and diminishes its activity mMCP-4 and human chymase share similar substrate specificity. 25 Therefore, we hypothesized that human chymase may also have the ability to downregulate FXIIIA via proteolysis. J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1
FXIIIA that was incubated with human skin chymase led to extensive fragmentation of FXIIIA, but not FXIIIB (Fig 5, A , and mass spectrometry data not shown). We performed in vitro cleavage reactions containing FXIIIA and increasing chymase concentrations to identify chymase cleavage sites. By focusing on the peptides identified in the FXIIIA samples that were incubated with the lowest utilized chymase concentration (0.001U), we identified peptides containing nontryptic termini that represent 6 potential chymase cleavage sites (Fig 5, B) . Using label-free quantitative mass spectrometry, we found that these putative chymase cleavage products increased in abundance with increasing chymase concentrations, as depicted for the cleavage site at F574 (Fig 5, C) . In addition, for 5 out of 6 of these high-affinity cleavage sites, we found that chymase cleavage followed aromatic residues (P1) (Fig 5, D) . Furthermore, the amino acids that were 2 residues upstream and downstream of the cleavage site (P3 and P29) were enriched for aliphatic or negatively charged residues (Fig 5, D) . These data are consistent with the reported substrate specificity for human chymase 25 and suggest that human chymase is sufficient to specifically cleave FXIIIA.
Interestingly, our mass spectrometric analysis of FXIIIA degradation showed that human chymase did not cleave FXIIIA at all the potential cleavage sites. One of the possible explanations is that chymase accessibility to certain cleavage sites may be reduced by the presence of charged or bulky amino acids in P4-P2 or P39-P49. In fact, cleavage at F574 may not be favored by chymase over other sites according to substrate specificity; however, 3D structure analysis revealed that F574 is a very accessible site for chymase cleavage (data not shown). To confirm that the FXIIIA fragmentation data obtained with our mass spectrometry analysis were derived from chymase activity, we designed a peptide (GVP) spanning the chymase site, F574, which could compete with FXIIIA for chymase-mediated cleavage (see Fig E5, A, in this article's Online Repository at www.jacionline. org). Our in vitro data indicated that GVP could prevent FXIIIA degradation by human chymase and Mcpt4 1/1 PCMC lysates (Fig E5, B and C) , indicating that FXIIIA fragmentation was caused by chymase proteolytic activity.
To assess whether chymase-mediated FXIIIA degradation leads to the generation of peptides with reduced biological activity, we performed a rotational thromboelastometry clot lysis assay with the FXIIIA digests. Chymase alone had no effect on fibrin clot formation by thromboelastography, indicating that chymase could not cleave and inactivate thrombin-activated FXIIIa when it was added simultaneously with FXIIIA and thrombin to this assay (data not shown). FXIIIA incubation with chymase before rotational thromboelastometry impaired the ability of FXIIIA to strengthen the fibrin clot (Fig 5, E) ; however, it did not affect clot stability (Fig 5, F) , demonstrating that FXIIIA cleavage by chymase leads to the generation of FXIIIA fragments with reduced biological activity. Chymase-deficient mice exhibit increased plasma FXIIIA levels and activity during experimental sepsis
Taking into account our in vitro data, we investigated whether chymase-FXIIIA interactions influence disease outcome. For this purpose, we investigated chymase-FXIIIA interactions in sepsis because fibrinolysis and its downregulation is a key component of the septic coagulation response, and increased FXIIIa activity levels correlate with disease severity and fatality in sepsis. 26 Mcpt4 1/1 mice exhibited a significant reduction in FXIIIA plasma and activity levels when compared with naive Mcpt4 1/1 mice (Fig 4, C, and Fig 6, A and B (Fig 4, A, and Fig 6, A and B (Fig 6, D) , suggesting that mMCP-4 mediated downregulation of FXIIIA plasma and activity levels at 24 hours after CLP impaired their capacity to stop bleeding. Therefore, these data demonstrate that mMCP-4 not only degrades FXIIIA in vitro but also reduces its function, which likely causes alterations in the clotting system during sepsis.
DISCUSSION
Accumulating in vitro and in vivo evidence indicates that mast cell functions may be much broader than their well-defined contribution to IgE-associated immune responses. In this study, we characterized mast cell releasates to further understand the contribution of mast cells to health and disease. For this purpose, we used proteomics as an unbiased approach to characterize mast cell secretomes. Previous studies used mass spectrometry analysis to dissect signaling pathways that are involved in IgEmediated mast cell activation [28] [29] [30] ; however, a characterization of the mediators that are released by mast cells on activation has not yet been reported. Therefore, we characterized the releasates generated by BMCMCs and PCMCs on IgE/antigenmediated activation. BMCMCs and PCMCs were used because these cells can be generated in the large numbers that are required for mass spectrometry analysis (25 million cells/treatment), and they are the closest in vitro ''surrogates'' to the 2 main murine mast cell subtypes, MMCs and CTMCs. Moreover, our BMCMC and PCMC culture conditions have been standardized and validated by us and other groups. However, we cannot dismiss the fact that the local microenvironment and the mechanisms of mast cell activation (IgE-dependent and IgE-independent) can influence the spectrum of mediators produced and released by mast cells from different locations during normal and pathological conditions. For example, we found that BMCMCs released reduced amounts of mast cell proteases on IgE/antigen activation; however, MMCs can upregulate certain proteases, such as the mast cell chymase, mMCP-1, during parasitic infections or following exposure to IL-9 or IL-10. 31 Therefore, further studies using alternative mass spectrometry methods that allow for low cell number usage will be important to replicate our work using freshly isolated cells from naive and challenged mice. In the meanwhile, the validation of unexpected or unknown mast cell mediators that are found by studying cultured mast cells may be possible by independent verification of their expression using databases such as the one provided by the Immunological Genome Project (ImmGen, http://www.immgen.org/ databrowser/) when complemented with targeted proteomics. By using Immgen, we retrieved information that freshly isolated mast cells from the trachea, tongue, esophagus, skin, and peritoneum express FXIIIA mRNA, as we found for BMCMCs and PCMCs.
The mechanisms that regulate and/or shape the extracellular proteomes that are generated by different mast cell populations are unclear. We found that releasates from IgE/antigen-activated PCMCs were enriched in mediators that are associated with proteolysis as a main biological function (Table I ). In contrast, releasates from IgE/antigen-activated BMCMCs contained a large number of mediators with immune regulatory capabilities and reduced proteolytic activity. From this observation, we hypothesized that proteolytic cleavage is a mechanism that can shape the profile of mediators produced by mast cells. For example, a mast cell type with a reduced number and/or diversity of proteases, such as BMCMCs, may be prone to regulate immune responses through the production of mediators, such as cytokines or chemokines, after IgE/antigen-mediated activation. Our proteomics findings were especially notable when we investigated how mast cells that express different protease profiles could differentially regulate the levels of the same mediator, FXIIIA, and affect its function during healthy and septic conditions. We focused our attention on FXIIIA due to its high abundance in the BMCMC releasates and undetectable levels in the PCMC releasates. On the basis of our proteomics findings pertaining to the protease profiles, we hypothesized that although BMCMCs contribute to FXIIIA production, PCMCs mainly contribute to FXIIIA degradation via proteolysis on IgE-mediated activation.
The capability of mast cells to secrete FXIIIA suggests that these cells may contribute to plasma FXIIIA levels in addition to the FXIIIA that is potentially produced by platelets and other myeloid cells. 32 However, we found that mast cell-deficient mice exhibited increased total and active FXIIIA plasma levels (Fig 3, A-C) . Moreover, mast cell-deficient mice also exhibited reduced bleeding times (Fig 3, D) . 17 Overall, these observations suggest that mast cells may significantly influence clotting processes through FXIIIA downregulation. Our findings with mMCP-4-deficient mice (Fig 4) suggest that chymase is involved in the downregulation of FXIIIA amounts and function under homeostatic conditions.
It has been shown that murine 33 and rat chymase 34 can be constitutively secreted by naive mast cells. Therefore, we think that constant or intermittent release of mast cell-derived chymase downregulates FXIIIA amounts and function. The mechanism by which mast cells release chymase in unchallenged rodents is unknown but it may involve piecemeal degranulation as observed for mast cells from the human intestine. (n 5 6) were sensitized with IgE mAb to DNP (2 mg/mL) overnight and then were challenged with DNP-HSA (100 ng/mL) for 6 hours. The cell supernatants were collected, concentrated, and subjected to
Human chymase degrades FXIIIA and diminishes its activity. A, Human FXIIIA was incubated with human skin chymase for 6 hours at 37 o C. FXIIIA fragmentation was assessed by silver stain analysis. The data are representative of those obtained from 3 independent experiments. B, A human FXIIIA domain map, including the conserved transglutaminase regions and the location of the detected chymase cleavage sites. C, FXIIIA was incubated with increasing concentrations of human skin chymase for 6 hours at 37 o C and then subjected to LC-MS/MS. Six chymase cleavage sites in FXIIIA produced a marked dose-response to the increasing chymase levels, as exemplified for cleavage site F574. D, An approximation of the consensus peptide sequence alignment patterns containing the detected chymase cleavage sites. Chymase cleavage occurs between P1 and P19. The peptide sequences shown were sorted in order of their negatively charged and aliphatic residues. E and F, ROTEM results are reported as maximal clot firmness (MCF) (Fig 5, E) , which represents fibrin polymerization, FXIIIa activity, and the lysis index 60 (LI60) (Fig 5, F) , which represents the percentage of the remaining clot in relation to the MCF value at 60 minutes after clot onset time. The data were pooled from 3 independent experiments. FBG, Fibrinogen; RO-TEM, rotational thromboelastometry.
shotgun proteomics. The FXIIIA abundance is expressed in spectral counts. B, PCMC lysates were incubated with human FXIIIA for the indicated time points at 378C. The FXIIIA levels and their fragments were assessed with Western blot analysis. The data are representative of those obtained in 2 independent experiments. Western blot analysis (C) and densitometry values (D) for plasma FXIIIA levels in Mcpt4 1/1 (n 5 5) and Mcpt4 2/2 (n 5 5) mice. E and F, FXIIIa activity levels (Fig 4, E) and tail tip bleeding times (Fig 4, F) in What is the relevance of FXIIIA-chymase interactions during disease? To answer this question, we used the CLP model of sepsis because diminished fibrinolysis is a key component of the septic coagulation response 36 and because we observed that chymase plays a key role in protecting from sepsis by proteolytically cleaving inflammatory mediators that exacerbate the disease. 4 We found that chymase deficiency in mice subjected to CLP partially restored their plasma FXIIIA levels to those observed in naive mice (Fig 3, B, and Fig 6, B) , suggesting that chymase released from activated mast cells may degrade FXIIIA during CLP. Notably, neutrophil elastase can also inactivate FXIIIA, 37 which makes our findings even more noteworthy considering that Mcpt4 2/2 mice exhibit an augmented hyperinflammatory response, which is mainly neutrophilic, during CLP. 4 Septic Mcpt4 2/2 mice exhibited reduced bleeding times, likely as a consequence of their increased FXIIIa activity levels (Fig 6, C and D) . However, we did not detect fibrin deposition in the kidneys of Mcpt4 2/2 mice, which is indicative of septic disseminated intravascular coagulation, a potential cause of acute kidney injury that Mcpt4 2/2 mice develop after CLP. 4 This evidence suggests that the increased FXIIIa activity levels we observed in the chymase-deficient mice did not cause significant coagulopathy alterations. These observations are consistent with the fact that severe CLP-induced sepsis, as is the septic phenotype that Mcpt4 2/2 mice develop after CLP surgery, is a weaker inducer of disseminated intravascular coagulation. 38 FXIII deficiency impairs myeloid cell migration 39, 40 and inflammation after myocardial infarction. 41 Therefore, FXIIIA may be able to contribute to the hyperinflammatory response that Mcpt4 2/2 mice develop after CLP, 4 by inducing myeloid cell mobilization.
We can only speculate for now on when mast cell-mediated production of FXIIIA may influence disease outcomes or may overcome its degradation by chymase. For example, mast cell-derived FXIIIA may prevent pathogen dissemination that contributes to pathogen entrapment into clots, 42 or contribute to the coagulopathies that are observed with systemic mastocytosis. 43 However, we should point out that this assumption comes with the caveats that mast cells produce other mediators with the ability to influence coagulation, such as heparin and tryptase, 44 and there are additional cellular sources of FXIIIA. 8 Moreover, mast cell activation in nonallergic disorders may involve certain IgE-independent stimuli to which CTMCs may be more responsive than MMCs, leading to a more pronounced reduction in FXIIIA levels and activity than that observed after IgE-dependent mast cell activation. Therefore, we believe that further studies will be necessary to assess the contribution of mast cell-derived FXIIIA to health and disease, ideally using mice with FXIIIA deficiency in mast cell-specific subsets.
The relevance of our murine findings regarding the contribution of FXIIIA-mast cell interactions in human homeostasis and disease still requires investigation. We performed a pilot study in which we investigated FXIIIA expression in nasal polyp mast cells from patients with chronic rhinosinusitis. We found that a subset of mast cells located in the epithelium submucosa and around the glands of nasal polyps expressed FXIIIA (see Fig E7 in this article's Online Repository at www.jacionline.org). Interestingly, FXIIIA-expressing cells within glands are rare. These observations correlate with the chymase expression levels that were recently reported for mast cells in nasal polyps, in which chymase expression levels were low in mast cells that were located in the epithelium and high for mast cells located in the nasal polyp glands. 45 These findings raise questions regarding the contribution of mast cells in nasal polyp development. In fact, our findings suggest that gland mast cells may have a beneficial effect by reducing excessive fibrin deposition in nasal polyps via chymase-mediated proteolytic degradation of FXIIIA that is produced by either mast cells themselves or by M2 macrophages. 46 
Conclusions
Overall, our studies in mice and humans suggest that mast cells have the ability to produce and degrade FXIIIA depending on their chymase expression profile: mast cells expressing chymase degrade FXIIIA, whereas mast cells that do not express chymase mainly produce FXIIIA. We believe that our findings exemplify a new level of complexity for mast cells in health and disease: the mast cell protease content can shape its extracellular mediator profile.
